Emyria Limited (EMD.XA)
Cboe AU · AUD
A$0.039 (+0.00%) as of
Key statistics
- EPS (TTM)
- -0.0270
- 52-week range
- 0.0360 – 0.0780
- Beta
- 0.02
- Revenue (TTM)
- 4.05M
- Profit margin
- -150.84%
- Volume
- 75.30k
About Emyria Limited
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Subiaco, Australia.
- Headquarters
- Subiaco, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.